Aqueous  ||| S:0 E:8 ||| JJ
humor  ||| S:8 E:14 ||| NN
and  ||| S:14 E:18 ||| CC
serum  ||| S:18 E:24 ||| JJ
concentrations  ||| S:24 E:39 ||| NNS
of  ||| S:39 E:42 ||| IN
soluble  ||| S:42 E:50 ||| JJ
MICA  ||| S:50 E:55 ||| NNP
and  ||| S:55 E:59 ||| CC
MICB  ||| S:59 E:64 ||| NNP
in  ||| S:64 E:67 ||| IN
glaucoma  ||| S:67 E:76 ||| JJ
patients  ||| S:76 E:85 ||| NNS
Immune  ||| S:85 E:92 ||| JJ
reactions  ||| S:92 E:102 ||| NNS
have  ||| S:102 E:107 ||| VBP
been  ||| S:107 E:112 ||| VBN
reported  ||| S:112 E:121 ||| VBN
to  ||| S:121 E:124 ||| TO
be  ||| S:124 E:127 ||| VB
involved  ||| S:127 E:136 ||| VBN
in  ||| S:136 E:139 ||| IN
the  ||| S:139 E:143 ||| DT
destruction  ||| S:143 E:155 ||| NN
of  ||| S:155 E:158 ||| IN
retinal  ||| S:158 E:166 ||| JJ
ganglion  ||| S:166 E:175 ||| NN
cells  ||| S:175 E:181 ||| NNS
( ||| S:181 E:182 ||| -LRB-
RGCs ||| S:182 E:186 ||| NNP
)  ||| S:186 E:188 ||| -RRB-
in  ||| S:188 E:191 ||| IN
glaucoma ||| S:191 E:199 ||| NN
.  ||| S:199 E:201 ||| .
To  ||| S:201 E:204 ||| TO
investigate  ||| S:204 E:216 ||| VB
the  ||| S:216 E:220 ||| DT
role  ||| S:220 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
major  ||| S:228 E:234 ||| JJ
histocompatibility  ||| S:234 E:253 ||| JJ
complex  ||| S:253 E:261 ||| JJ
class  ||| S:261 E:267 ||| NN
I-related  ||| S:267 E:277 ||| JJ
chain  ||| S:277 E:283 ||| NN
A  ||| S:283 E:285 ||| NN
and  ||| S:285 E:289 ||| CC
B  ||| S:289 E:291 ||| NNP
( ||| S:291 E:292 ||| -LRB-
MICA  ||| S:292 E:297 ||| NNP
and  ||| S:297 E:301 ||| CC
MICB ||| S:301 E:305 ||| NNP
)  ||| S:305 E:307 ||| -RRB-
molecules  ||| S:307 E:317 ||| NNS
in  ||| S:317 E:320 ||| IN
the  ||| S:320 E:324 ||| DT
pathogenesis  ||| S:324 E:337 ||| NN
of  ||| S:337 E:340 ||| IN
glaucoma ||| S:340 E:348 ||| NN
.  ||| S:348 E:350 ||| .
Aqueous  ||| S:350 E:358 ||| JJ
humor  ||| S:358 E:364 ||| NN
and  ||| S:364 E:368 ||| CC
serum  ||| S:368 E:374 ||| JJ
samples  ||| S:374 E:382 ||| NNS
from  ||| S:382 E:387 ||| IN
15  ||| S:387 E:390 ||| CD
glaucoma  ||| S:390 E:399 ||| CD
patients  ||| S:399 E:408 ||| NNS
and  ||| S:408 E:412 ||| CC
45  ||| S:412 E:415 ||| CD
patients  ||| S:415 E:424 ||| NNS
with  ||| S:424 E:429 ||| IN
cataract ||| S:429 E:437 ||| NN
,  ||| S:437 E:439 ||| ,
undergoing  ||| S:439 E:450 ||| VBG
ocular  ||| S:450 E:457 ||| JJ
surgery ||| S:457 E:464 ||| NN
,  ||| S:464 E:466 ||| ,
were  ||| S:466 E:471 ||| VBD
obtained ||| S:471 E:479 ||| VBN
.  ||| S:479 E:481 ||| .
The  ||| S:481 E:485 ||| DT
concentrations  ||| S:485 E:500 ||| NNS
of  ||| S:500 E:503 ||| IN
MICA  ||| S:503 E:508 ||| NNP
and  ||| S:508 E:512 ||| CC
MICB  ||| S:512 E:517 ||| NNP
molecules  ||| S:517 E:527 ||| NNS
in  ||| S:527 E:530 ||| IN
all  ||| S:530 E:534 ||| DT
samples  ||| S:534 E:542 ||| NNS
were  ||| S:542 E:547 ||| VBD
measured  ||| S:547 E:556 ||| VBN
using  ||| S:556 E:562 ||| VBG
ELISA ||| S:562 E:567 ||| NNP
.  ||| S:567 E:569 ||| .
Both  ||| S:569 E:574 ||| DT
MICA  ||| S:574 E:579 ||| NNP
and  ||| S:579 E:583 ||| CC
MICB  ||| S:583 E:588 ||| NNP
concentrations  ||| S:588 E:603 ||| NNS
were  ||| S:603 E:608 ||| VBD
higher  ||| S:608 E:615 ||| JJR
in  ||| S:615 E:618 ||| IN
the  ||| S:618 E:622 ||| DT
aqueous  ||| S:622 E:630 ||| JJ
humor  ||| S:630 E:636 ||| NN
of  ||| S:636 E:639 ||| IN
patients  ||| S:639 E:648 ||| NNS
with  ||| S:648 E:653 ||| IN
glaucoma  ||| S:653 E:662 ||| VBG
compared  ||| S:662 E:671 ||| VBN
to  ||| S:671 E:674 ||| TO
those  ||| S:674 E:680 ||| DT
with  ||| S:680 E:685 ||| IN
cataract  ||| S:685 E:694 ||| NN
( ||| S:694 E:695 ||| -LRB-
p=0.013  ||| S:695 E:703 ||| NNP
and  ||| S:703 E:707 ||| CC
p=0.004 ||| S:707 E:714 ||| NNP
,  ||| S:714 E:716 ||| ,
respectively ||| S:716 E:728 ||| RB
) ||| S:728 E:729 ||| -RRB-
;  ||| S:729 E:731 ||| :
however ||| S:731 E:738 ||| RB
,  ||| S:738 E:740 ||| ,
in  ||| S:740 E:743 ||| IN
the  ||| S:743 E:747 ||| DT
serum  ||| S:747 E:753 ||| JJ
samples ||| S:753 E:760 ||| NNS
,  ||| S:760 E:762 ||| ,
no  ||| S:762 E:765 ||| DT
significant  ||| S:765 E:777 ||| JJ
differences  ||| S:777 E:789 ||| NNS
were  ||| S:789 E:794 ||| VBD
observed ||| S:794 E:802 ||| VBN
.  ||| S:802 E:804 ||| .
Increased  ||| S:804 E:814 ||| VBN
intraocular  ||| S:814 E:826 ||| JJ
pressure  ||| S:826 E:835 ||| NN
may  ||| S:835 E:839 ||| MD
be  ||| S:839 E:842 ||| VB
associated  ||| S:842 E:853 ||| VBN
with  ||| S:853 E:858 ||| IN
increased  ||| S:858 E:868 ||| JJ
expression  ||| S:868 E:879 ||| NN
of  ||| S:879 E:882 ||| IN
the  ||| S:882 E:886 ||| DT
MICA  ||| S:886 E:891 ||| NNP
and  ||| S:891 E:895 ||| CC
MICB  ||| S:895 E:900 ||| NNP
molecules ||| S:900 E:909 ||| NNS
,  ||| S:909 E:911 ||| ,
which  ||| S:911 E:917 ||| WDT
could  ||| S:917 E:923 ||| MD
initiate  ||| S:923 E:932 ||| VB
the  ||| S:932 E:936 ||| DT
destruction  ||| S:936 E:948 ||| NN
of  ||| S:948 E:951 ||| IN
RGCs  ||| S:951 E:956 ||| JJ
and  ||| S:956 E:960 ||| CC
consequent  ||| S:960 E:971 ||| JJ
development  ||| S:971 E:983 ||| NN
of  ||| S:983 E:986 ||| IN
glaucoma ||| S:986 E:994 ||| NN
.  ||| S:994 E:996 ||| .
